Skip to Content
MilliporeSigma
All Photos(1)

Documents

H-922

Supelco

α-Hydroxymidazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H13ClFN3O
CAS Number:
Molecular Weight:
341.77
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

SMILES string

OCc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4-n12

InChI

1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2

InChI key

QHSMEGADRFZVNE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

α-Hydroxymidazolam is an active, major metabolite in urine and blood of the benzodiazepine midazolam. Midazolam is sold as Dormicum, Hypnovel®, and Versed as a sedative and treatment for insomnia and seizures. This Certified Spiking Solution® is suitable as starting material for use in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.

Application


  • Pharmacodynamic studies: α-Hydroxymidazolam is utilized in pharmacodynamic research to compare the effects of midazolam and its metabolites on neuronal activity. The study provides insight into the depressant effects on the neocortical neuronal network, aiding in the understanding of benzodiazepine drug actions (Balk et al., 2017).

  • Metabolic pathway research: Research explores the use of α-Hydroxymidazolam in studying drug-drug interactions and metabolism in cytochrome P450 knockout mice. This application highlights its role in examining metabolic pathways and interactions that affect drug metabolism, crucial for drug development and therapy optimization (Grimsley et al., 2013).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Hypnovel is a registered trademark of Hoffman-LaRoche & Co. AG
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

7-Aminonitrazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-913

7-Aminonitrazepam solution

α-Hydroxytriazolam

Sigma-Aldrich

H2529

α-Hydroxytriazolam

Quetiapine fumarate solution 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

Q-001

Quetiapine fumarate solution

Cocaethylene solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-010

Cocaethylene solution

USP

USP

1443599

Midazolam

Zolpidem solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

Z-017

Zolpidem solution

Alprazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-903

Alprazolam solution

Kristin Samuelsson et al.
Xenobiotica; the fate of foreign compounds in biological systems, 42(11), 1128-1137 (2012-05-31)
The pharmacokinetics and biotransformation of midazolam were investigated following single oral doses of 0.1, 1 and 10 mg/kg to chimeric mice with humanised livers (PXB mice) and to severe combined immunodeficient (SCID) mice used as controls. Pharmacokinetic analysis, on whole
Varun Garg et al.
Journal of clinical pharmacology, 52(10), 1566-1573 (2011-12-14)
In this open-label study, 24 healthy volunteers received a single intravenous (IV) dose of 0.5 mg of midazolam on day 1 and a single oral dose each of 2 mg of midazolam and 0.5 mg of digoxin on day 3.
Theo de Boer et al.
Biomedical chromatography : BMC, 25(10), 1112-1123 (2011-02-03)
An early clinical development study (phase I) was conducted to determine the usefulness of dried blood spot (DBS) sampling as an alternative to venous sampling for phenotyping and genotyping of CYP450 enzymes in healthy volunteers. Midazolam (MDZ) was used as
Stephanie Katzenmaier et al.
European journal of clinical pharmacology, 66(11), 1137-1141 (2010-08-04)
Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam
David Hostler et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(5), 781-788 (2010-02-19)
The clinical use of therapeutic hypothermia has been rapidly expanding due to evidence of neuroprotection. However, the effect of hypothermia on specific pathways of drug elimination in humans is relatively unknown. To gain insight into the potential effects of hypothermia

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service